CN Patent

CN121197111A — 依达拉奉口腔溶膜速释制剂组合物及其制剂和用途

Assigned to Deuracor Therapeutic Inc · Expires 2025-12-26 · 0y expired

What this patent protects

本申请公开了依达拉奉膜速释制剂组合物，其包含依达拉奉或其药学可接受的其盐、前药、代谢产物、溶剂化物、晶体、或氘代物以及辅料，基于所述组合物的重量，所述依达拉奉或其药学可接受的其盐、前药、代谢产物、溶剂化物、晶体、或氘代物的重量百分比为1％‑60％。本申请的依达拉奉口腔溶膜速释制剂用于舌下给药，具有崩解快、口感好的特点。

USPTO Abstract

本申请公开了依达拉奉膜速释制剂组合物，其包含依达拉奉或其药学可接受的其盐、前药、代谢产物、溶剂化物、晶体、或氘代物以及辅料，基于所述组合物的重量，所述依达拉奉或其药学可接受的其盐、前药、代谢产物、溶剂化物、晶体、或氘代物的重量百分比为1％‑60％。本申请的依达拉奉口腔溶膜速释制剂用于舌下给药，具有崩解快、口感好的特点。

Drugs covered by this patent

Patent Metadata

Patent number
CN121197111A
Jurisdiction
CN
Classification
—
Expires
2025-12-26
Drug substance claim
No
Drug product claim
No
Assignee
Deuracor Therapeutic Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.